Abstract 1554P
Background
In India public spending on health is 1.5% of the GDP, which is far lower than most countries in the world. The poor public expenditure on health has led to mushrooming of private care, with 60% of hospitalization and 70% outpatient care being offered now by the private hospitals. Private treatment is expensive leading to OOP and catastrophic expenditure. Furthermore, insurance penetration in India is less than 20% adding to the financial woes. Those insured also have to resort to OOP for outpatient services, rehabilitation, supportive care, drugs, disposables and copayments. Copayments vary according to disease, type of policy, age of insured, drug administered, premium limit among other factors.
Methods
All adult insured patients who underwent treatment in the Department of Medical Oncology from April 1 2023 to March 31 2024 were included in the study. This is a retrospective cross sectional observational study.
Results
A total of 236 patients were included in the study comprising 79 (33.4%) males and 157 (66.6%) females. Commonest cancers were Breast (29.6%) and Lung (11%). Most patients were in the age group 41-60 (43.2%) and 61-80 (40.6%) respectively. Co payment was calculated as: amount spent by patient / total insurance approved amount x 100. Average insurance approved amount was 947 USD. Average co payment was 151 USD (16% of approved amount). 105 patients had < 1% (44.4%), while 87 patients (36.8%) had 1-20% co payment. 6.35% had more than 60% co payment expenditure. 50 patients (21.1%) had their claims completely taken care of. Classified for gender copayments amongst men vs women were 61 (77.21%) vs 125 (79.6%) respectively. 96% patients taking Immunotherapy resorted to OOP. Their copayments were almost double of the average (291 USD), while their approved amounts were less than the mean (864 USD).
Conclusions
Insurance for Cancer patients is essential to ensure access to care. Copayments lead to OOP in insured patients. In our study 78% patients had some form of copayment. While most patients had < 1% copayment, 15% had more than 60% OOP. Average copayment was 16% of the total approved amount. OOP was higher among Immunotherapy patients with lesser approved amounts. Measures to reduce copayments and OOP for insured patients is essential to maintain continuity of Cancer care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1199P - Developing and systematically validating homologous recombination repair gene detection method based on next-generation sequencing
Presenter: Yi Sun
Session: Poster session 10
1200P - Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutes
Presenter: Martí Homs Soler
Session: Poster session 10
1201P - Novel deep learning model and validation of whole slide images in lung cancer diagnosis
Presenter: Alhassan Ahmed
Session: Poster session 10
Resources:
Abstract
1202P - A deep learning approach using routine pathology images to guide precision medicine in metastatic CRC
Presenter: Chaitanya Parmar
Session: Poster session 10
1203P - Analytical evaluation of whole genome sequencing for acute myeloid leukemia
Presenter: Guidantonio Malagoli Tagliazucchi
Session: Poster session 10
1204P - Real-world utility of whole genome sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 genomes project
Presenter: Helen Robbins
Session: Poster session 10
1205P - A retrospective machine learning-based analysis of nationwide cancer CGP data across cancer types to identify features associated with recommendation of mutation-based therapy
Presenter: Hiroaki Ikushima
Session: Poster session 10
1478P - Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain management
Presenter: Yoshihiko Fujita
Session: Poster session 10
1479P - Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study
Presenter: Pablo Gallardo Melo
Session: Poster session 10
1480P - Long term therapy with denosumab and zoledronic acid: A comparative real-world retrospective observational study on skeletal-related events and pain in patients with metastatic breast cancer
Presenter: Giacomo Massa
Session: Poster session 10